SG10201803812TA - Neuroactive steroids, compositions, and uses thereof - Google Patents
Neuroactive steroids, compositions, and uses thereofInfo
- Publication number
- SG10201803812TA SG10201803812TA SG10201803812TA SG10201803812TA SG10201803812TA SG 10201803812T A SG10201803812T A SG 10201803812TA SG 10201803812T A SG10201803812T A SG 10201803812TA SG 10201803812T A SG10201803812T A SG 10201803812TA SG 10201803812T A SG10201803812T A SG 10201803812TA
- Authority
- SG
- Singapore
- Prior art keywords
- disorders
- compositions
- treatment
- steroids
- neuroactive steroids
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
Abstract
NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): (I) and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS- related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus. [No Suitable Figure]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014078820 | 2014-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201803812TA true SG10201803812TA (en) | 2018-06-28 |
Family
ID=54698130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609813XA SG11201609813XA (en) | 2014-05-29 | 2015-05-29 | Neuroactive steroids, compositions, and uses thereof |
| SG10201803812TA SG10201803812TA (en) | 2014-05-29 | 2015-05-29 | Neuroactive steroids, compositions, and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609813XA SG11201609813XA (en) | 2014-05-29 | 2015-05-29 | Neuroactive steroids, compositions, and uses thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20180179247A1 (en) |
| EP (3) | EP3149018B1 (en) |
| JP (4) | JP6652934B2 (en) |
| KR (2) | KR20240066304A (en) |
| CN (3) | CN114369135A (en) |
| AR (2) | AR100691A1 (en) |
| AU (4) | AU2015266447A1 (en) |
| CA (1) | CA2949720A1 (en) |
| CY (1) | CY1124109T1 (en) |
| DK (2) | DK3705488T3 (en) |
| ES (2) | ES2927007T3 (en) |
| HR (2) | HRP20221294T1 (en) |
| HU (2) | HUE059829T2 (en) |
| IL (3) | IL292461B2 (en) |
| JO (1) | JO3691B1 (en) |
| LT (2) | LT3149018T (en) |
| MX (4) | MX2016015532A (en) |
| PH (1) | PH12016502342A1 (en) |
| PL (2) | PL3149018T3 (en) |
| PT (2) | PT3705488T (en) |
| RS (2) | RS63554B1 (en) |
| RU (2) | RU2019126637A (en) |
| SG (2) | SG11201609813XA (en) |
| SI (2) | SI3705488T1 (en) |
| TW (1) | TW201625661A (en) |
| WO (1) | WO2015180679A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008006888A (en) | 2005-11-28 | 2008-09-30 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof. |
| EP3572417A3 (en) | 2011-10-14 | 2020-03-25 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| PL2986624T3 (en) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
| US9512165B2 (en) | 2013-04-17 | 2016-12-06 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HUE059829T2 (en) * | 2014-05-29 | 2022-12-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN117024501A (en) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | Compositions and methods for targeting CNS disorders |
| NZ769042A (en) | 2014-10-16 | 2023-12-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| PT3224269T (en) | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| SI3250210T1 (en) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2016338672A1 (en) | 2015-10-16 | 2018-04-12 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| JOP20170059B1 (en) * | 2016-03-08 | 2021-08-17 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| CN109689673B (en) | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17, C20 and C21 substituted neuroactive steroids and methods of use thereof |
| KR102518846B1 (en) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | Methods and compositions for the treatment of epileptic disorders |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| KR20200096596A (en) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Deuterated 21-[4-cyano-pyrazole-1-yl]-19-nor-pregan-3 for the treatment of CNS disorders. Alpha-ol-20-one derivative |
| US20210139530A1 (en) | 2018-02-11 | 2021-05-13 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| CN109503694A (en) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | A kind of novel GABAAReceptor modulators and application thereof |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| TW202043204A (en) * | 2019-01-14 | 2020-12-01 | 中國大陸商北京軒義醫藥科技有限公司 | Tetrazolone substituted steroids and use thereof |
| BR112021024033A2 (en) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Neuroactive steroids and their compositions |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| KR20220066262A (en) | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | Salts and crystalline forms of steroid derivative modulators |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN114828889A (en) | 2019-12-06 | 2022-07-29 | 马瑞纳斯制药公司 | Ganaxolone for the treatment of tuberous sclerosis |
| AU2022214187A1 (en) | 2021-01-28 | 2023-07-13 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| WO2023009584A1 (en) | 2021-07-28 | 2023-02-02 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| TW202341997A (en) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3634717A1 (en) * | 1986-10-11 | 1988-04-14 | Dynamit Nobel Ag | METHOD FOR PRODUCING 5-METHYLTETRAZOLE |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| PT1038880E (en) * | 1994-02-14 | 2008-01-29 | Euro Celtique Sa | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| CA2372342A1 (en) * | 1999-04-29 | 2000-11-09 | Derk J. Hogenkamp | 3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity |
| WO2004036372A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Scoring of sensed neurological signals for use with a medical device system |
| US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
| EP3572417A3 (en) * | 2011-10-14 | 2020-03-25 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| HUE059829T2 (en) * | 2014-05-29 | 2022-12-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions and uses thereof |
| NZ769042A (en) * | 2014-10-16 | 2023-12-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
-
2015
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/en unknown
- 2015-05-29 SI SI201531879T patent/SI3705488T1/en unknown
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/en active Application Filing
- 2015-05-29 PT PT201716701T patent/PT3705488T/en unknown
- 2015-05-29 RS RS20220848A patent/RS63554B1/en unknown
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/en unknown
- 2015-05-29 SI SI201531252T patent/SI3149018T1/en unknown
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 AR ARP150101717A patent/AR100691A1/en active IP Right Grant
- 2015-05-29 PL PL15799762T patent/PL3149018T3/en unknown
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/en active Active
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/en unknown
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/en active IP Right Grant
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 ES ES20171670T patent/ES2927007T3/en active Active
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/en active
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/en unknown
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/en active
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/en active Pending
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/en active Pending
- 2015-05-29 MX MX2016015532A patent/MX2016015532A/en unknown
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/en unknown
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/en unknown
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/en active Pending
- 2015-05-29 ES ES15799762T patent/ES2805598T3/en active Active
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/en unknown
- 2015-05-29 TW TW104117532A patent/TW201625661A/en unknown
- 2015-05-29 PT PT157997628T patent/PT3149018T/en unknown
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/en active
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 RS RS20200799A patent/RS60529B1/en unknown
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/en active
-
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/en unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/en unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/en unknown
-
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
-
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/en active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-17 HR HRP20201126TT patent/HRP20201126T1/en unknown
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/en unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
-
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/en unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/en active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
-
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/en active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en active Pending
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502342A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| MX2022007490A (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof. | |
| CY1124175T1 (en) | 19-NOR NEUROACTIVE STEROIDS FOR THERAPEUTIC METHODS | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2023001876A (en) | Rapamycin derivatives. | |
| PH12016502582A1 (en) | TrK-INHIBITING COMPOUND | |
| GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| MX2016015248A (en) | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy. | |
| UA109459C2 (en) | 5,6-Dihydroimidazo derivatives [1,2-a] Pyrazine-8-ylamine, Suitable as BACE-SECRETASE INHIBITORS (BACE) | |
| WO2011097946A8 (en) | Oxazolidinone compounds containing ring-fused bicyclic ring, preparation method and use thereof | |
| MX2013008056A (en) | 1,4-oxazepines as bace1 and/or bace2 inhibitors. | |
| MX2019007101A (en) | Oxazine derivatives as beta-secretase inhibitors and methods of use. | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MY196807A (en) | Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use | |
| MX2019007102A (en) | Thiazine derivatives as beta-secretase inhibitors and methods of use. | |
| MX2016015180A (en) | Fused triazole derivatives as phosphodiesterase 10a inhibitors. | |
| MX2013002956A (en) | Arylosulfonamides for the treatment of cns diseases. | |
| GEP20156227B (en) | Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same | |
| MX2017009853A (en) | Prevention or treatment of uric acid or gout disease. | |
| NZ764941B2 (en) | Neuroactive steroids, compositions, and uses thereof | |
| MD20160115A2 (en) | Novel combination between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-G][1,2,3]benzotriazine-4,9-dione and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing same | |
| UA107356C2 (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders | |
| GEP20135801B (en) | New compounds of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them |